Genexine Announces Merger with EPD Biotherapeutics to Strengthen Drug Development Pipeline

Merger with EPD Bio, a biotech developing a target protein degrader (TPD) platform technology Jaehyun Choi, Ph.D. founder and CEO of EPD Bio, joins Genexine as head of R&D

Jun 26, 2024Genexine

Genexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)

First market approval for Genexine discovered and developed therapeutic drug, Efesa (Efepoetin alfa), a long-acting erythropoietin (EPO) for the treatment of Chronic Kidney disease Induced anemia

Oct 23, 2023Genexine

Genexine’s long-acting growth hormone meets Phase 3 primary endpoint

Phase 3 clinical trial in China meets primary endpoint On track to file BLA in China in 2024

Aug 30, 2023Genexine

Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting

Triple combination using Genexine’s DNA vaccine GX-188E, its long-acting Interleukin-7 GX-I7 and Keytruda showed a major pathological response rate of 63.6% in a phase 2 trial, satisfying primary evaluation criteria

May 26, 2023Genexine

Genexine’s long-acting anemia treatment GX-E4 phase 3 clinical trial interim result is presented at WCN2023, confirmed non-inferiority compared to Mircera.

confirmed non-inferiority compared to Mircera

Apr 11, 2023Genexine